Jyong Biotech Plunges 10.98% Despite IPO Surge

On June 18, 2025, Jyong Biotech experienced a significant drop of 10.98% in pre-market trading, marking a notable decline in its stock performance.

Jyong Biotech Ltd., a Taiwan-based biotech company, recently priced its initial public offering (IPO) at $7.50 per share, which is at the lower end of the expected range. Despite the lower pricing, the company's shares soared on their debut on the NASDAQ, indicating strong investor interest in its drug development initiatives.

The company announced the pricing of a $20 million initial public offering, which is a significant milestone for Jyong Biotech. This IPO is expected to provide the company with the necessary capital to further its research and development efforts, potentially driving future growth and innovation in the biotech sector.